Your session is about to expire
← Back to Search
PMPA Prodrug for HIV
Study Summary
This trial is testing the safety of a new drug for HIV, as well as how well it works and how it is metabolized.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any strong medications or treatments that could harm my kidneys in the last 2 weeks.I am currently on antiretroviral therapy for HIV.I have recovered from a serious infection and it's been 2 weeks since I stopped taking IV antibiotics.I have been on Adefovir dipivoxil for over two weeks.I am HIV positive, confirmed by a test.I do not have serious heart problems like chest pain, heart failure, or irregular heartbeat.I have a cancer type other than basal cell carcinoma or cutaneous Kaposi's sarcoma.I haven't taken any HIV medication in the last 2 weeks.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants aged 55 or older eligible to enroll in the experiment?
"This clinical trial has established that only those aged 18-60 are eligible for enrollment. For individuals below the age of consent, there are 108 studies available; whereas, 353 tests exist for patients over 65 years old."
Are there any eligibility criteria for participating in this clinical experiment?
"This medical research requires 60 participants ranging from 18 to 60 years old, diagnosed with HIV. Additionally, they must have a CD4 cell count of 200 or more cells/mm3 within 28 days prior to study entry., plasma HIV RNA of 10,000 copies/ml and a life expectancy exceeding 1 year."
What safety precautions have been taken to ensure the well-being of subjects using this treatment?
"Due to the limited clinical evidence that supports safety and efficacy of this treatment, it receives a score of 1 on our risk-assessment scale."
Share this study with friends
Copy Link
Messenger